Crescent Biopharma (CBIO) Invested Capital (2013 - 2026)

Crescent Biopharma (CBIO) has 14 years of Invested Capital data on file, last reported at $183.8 million in Q1 2026.

• Invested Capital for Q1 2026 came in at $183.8 million, up 709.55% year-over-year; the trailing twelve-month figure through Mar 2026 was $183.8 million (up 709.55% YoY), and the FY2025 annual result was $203.0 million, up 1411.53% from the prior year.
• Invested Capital eased to $183.8 million in Q1 2026 per CBIO's latest filing, from $203.0 million in the prior quarter.
• Over five years, Invested Capital peaked at $203.0 million in Q4 2025 and troughed at -$30.2 million in Q1 2025.
• A 5-year average of $62.4 million and a median of $48.1 million in 2022 frame the typical range for Invested Capital.
• On a YoY basis, Invested Capital climbed as much as 9058.6% in 2025 and fell as far as 204.32% in 2025.
• A 5-year view of Invested Capital shows it stood at $42.9 million in 2022, then fell by 10.52% to $38.4 million in 2023, then plunged by 140.29% to -$15.5 million in 2024, then surged by 1411.53% to $203.0 million in 2025, then fell by 9.44% to $183.8 million in 2026.
• Business Quant data shows CBIO's Invested Capital at $183.8 million in Q1 2026, $203.0 million in Q4 2025, and $116.6 million in Q3 2025.